These therapies, which include inhibitors of tumor necrosis factor (TNF), interleukin (IL)-1, and IL-6, and more recently IL17 inhibitors and janus kinase inhibitors, offer a more targeted approach, addressing the underlying inflammatory processes of the various JIA types [17–19]. Here, TNF is linked to juvenile idiopathic arthritis.